Chewy Stock Faces Challenges

1 Mins read

Chewy (ticker: CHWY), the online pet-supplies retailer, is experiencing a downturn in its stock value, with its ninth decline in 10 trading sessions. Rupesh Parikh, an analyst at Oppenheimer, downgraded the shares of Chewy to Perform from Outperform. Parikh also removed his prior price target of $35.

In morning trading, Chewy’s stock was down 3.2% to $18.82, putting it on track to close at a record low, according to Dow Jones Market Data. The stock has been setting new lows consistently since September 12th.

Parikh highlighted the challenges facing Chewy in a research note, noting recent signs of weakness in the pet food category. He expects a more challenging environment to persist over the coming quarters.

Chewy’s second fiscal quarter results, announced on August 30th, surprisingly showed a profit and higher revenue than expected. However, the number of active users had declined compared to the same period last year. Chief Executive Sumit Singh attributed this decline to consumers opting for lower-priced dry food due to inflation.

Parikh’s concerns are echoed by Evercore ISI analyst Mark Mahaney, who downgraded Chewy to In Line from Outperform and lowered his price target to $35 from $53 following the earnings report. Mahaney expressed concerns about market maturity in the US, intense competition from giants like Amazon and Walmart, and uncertainty surrounding Chewy’s expansion plans in Canada.

While Parikh remains optimistic about Chewy’s longer-term prospects, he awaits definitive signs of progress and a potential reset of market expectations.

Related posts

GitLab Stock Surges on First Ever Adjusted Operating Profit

1 Mins read
GitLab’s stock experienced a significant surge on Tuesday following the announcement of its first ever adjusted operating profit. Despite this positive development,…

Virgin Galactic Faces Stock Decline Amid Founder's Money Decision

2 Mins read
Virgin Galactic stock experienced a sharp decline in early trading on Monday due to founder Richard Branson’s announcement that he won’t be…

EyePoint Pharmaceuticals Announces Positive Results in Phase 2 Trial for Macular Degeneration Treatment

1 Mins read
EyePoint Pharmaceuticals, a Massachusetts-based company, revealed exciting news on Monday regarding the second-phase trial of its investigational treatment for macular degeneration. The…

Leave a Reply

Your email address will not be published. Required fields are marked *

62 − 56 =